The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 3 of the 7 sources its claims cite were checked for support.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Open accessAbstract
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. RESULTS: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events. CONCLUSIONS: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
38 Own result · 11 Own method · 3 Own interpretation · 2 No full text of the sources · 1 Supported · 1 Partly supported · 1 Sources not found · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
What the sources say
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The Results (p. 1) report that sitagliptin lowered glycated hemoglobin but did not reduce the primary cardiovascular outcome; Other Secondary Outcomes (p. 4) show no reduction in death from any cause. These findings support the lack of a demonstrated benefit for sitagliptin in this trial, but do not establish the broader claim about glucose lowering generally. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [6] source
The paper says uncertainty remains about whether glucose-lowering strategies can reduce cardiovascular risk; it notes that most trials had not shown a significant cardiovascular benefit, while acknowledging possible exceptions for metformin and insulin. The Discussion likewise says that whether improved glycemic control reduces macrovascular events remains in question. Its reported death outcomes do not show a significant reduction. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Fatal or nonfatal stroke | 69 (3.0) | 10.5 | 164 (3.5) | 12.3 | 1.18 (”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“P<0.001 for noninferiority”
plainn = 4,687- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of death from any cause in which it was assumed that all patients who were lost to follow-up in the empagliflozin group died and all patients who were lost to follow-up in the placebo group were alive showed a significant benefit of empagliflozin versus placebo (hazard ratio, 0.77; 95% CI, 0.65 to 0.93; P = 0.005).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: In the sensitivity analysis of death from any cause, all patients lost to follow-up in the empagliflozin group were assumed to have died and all patients lost to follow-up in the placebo group were assumed to be alive.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In subgroup analyses, there was some heterogeneity for the primary outcome.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant between-group difference in the key secondary outcome (P = 0.08 for superiority).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no relevant changes in electrolytes in the two study groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All categories of death from cardiovascular causes contributed to the reduction in cardiovascular death in the empagliflozin group”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with type 2 diabetes at high risk for cardiovascular events, those receiving empagliflozin had a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than did patients receiving placebo.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with no significant between-group difference in the risk of myocardial infarction or stroke.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 16
- The quote only partly states this claim. 4
- It may state two separate claims as one. 20
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inhibitors of sodium-glucose cotransporter 2 reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion. 10”
What the sources say
- Supportedcites [10] source
The Introduction states that SGLT2 inhibitors block renal glucose reabsorption, increase urinary glucose excretion, and have anti-hyperglycaemic effects. The Conclusion also states that SGLT2 inhibition lowers renal glucose reabsorption and blood glucose levels and may be effective in type 2 diabetes. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Genital infection was reported in a higher percentage of patients in the pooled empagliflozin group.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A higher percentage of patients in the placebo group received additional glucose-lowering medications (including sulfonylurea and insulin), antihypertensive medications (including diuretics), and anticoagulants during the trial, with no between-group difference in the receipt of lipidlowering drugs”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Over the course of the study, empagliflozin, as compared with placebo, was associated with small reductions in weight, waist circumference, uric acid level, and systolic and diastolic blood pressure with no increase in heart rate and small increases in both LDL and HDL cholesterol”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“at week 206, the differences were -0.24 percentage points (95% CI, -0.40 to -0.08) and -0.36 percentage points (95% CI, -0.51 to -0.20).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Myocardial infarction was reported in 4.8% of patients in the empagliflozin group and 5.4% of those in the placebo group, and stroke in 3.5% and 3.0% of patients, respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Urosepsis was reported in 0.4% of patients in the empagliflozin group and 0.1% of those in the placebo group, but there was no imbalance in overall rates of urinary tract infection, complicated urinary tract infection, or pyelonephritis”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 12 weeks, during which glucose-lowering therapy was to remain unchanged, the adjusted mean differences in the glycated hemoglobin level between patients receiving empagliflozin and those receiving placebo were -0.54 percentage points (95% CI, -0.58 to -0.49) in the 10-mg group and -0.60 percentage points (95% CI, -0.64 to -0.55) in the 25-mg group”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction)”
- Also stated in: § CONCLUSIONS · p. 1 · plain
“Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Also stated in: § CONCLUSIONS · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients who had adverse events, serious adverse events, and adverse events leading to the discontinuation of a study drug were similar in the empagliflozin group and the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients with diabetic ketoacidosis, volume depletion, thromboembolic events, and bone fracture were low (ranging from <1% for ketoacidosis and thromboembolic events to 5% for volume depletion) and similar in the empagliflozin groups and the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant between-group differences in the rates of myocardial infarction or stroke”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction)”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematocrit values were higher in the empagliflozin groups than in the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients with confirmed hypoglycemic adverse events, acute renal failure, diabetic ketoacidosis, thromboembolic events, bone fracture, and events consistent with volume depletion were similar in the two study groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the percentage of patients with acute renal failure (including acute kidney injury) was lower in the empagliflozin groups than in the placebo group, and renal function was maintained with empagliflozin.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratios for the primary outcome were 0.85 (95% CI, 0.72 to 1.01; P = 0.07) for the 10-mg dose of empagliflozin versus placebo and 0.86 (95% CI, 0.73 to 1.02; P = 0.09) for the 25-mg dose versus placebo.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction)”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the point estimate for the hazard ratio for stroke was closer to 1.00”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the primary and key secondary outcomes, hazard ratios for the comparison between the 10-mg dose of empagliflozin versus placebo and the 25-mg dose versus placebo were virtually identical to those in the pooled analysis, but the individual dose effects were not significant”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“there is concern that intensive glucose lowering or the use of specific glucose-lowering drugs may be associated with adverse cardiovascular outcomes. 8”
What the sources say
- Not checked — no full text of the sourcecites [8] source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Empagliflozin is a selective inhibitor of sodium glucose cotransporter 2 11”
What the sources say
- Not checked — no full text of the sourcecites [11] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was performed with the use of a computer-generated random-sequence and interactive voice- and Web-response system and was stratified according to the glycated hemoglobin level at screening (<8.5% or ≥8.5%), bodymass index at randomization (<30 or ≥30), renal function at screening (eGFR, 30 to 59 ml, 60 to 89 ml, or ≥90 ml per minute per 1.73 m 2 ), and geographic region”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed the primary analysis using a modified intention-to-treat approach among patients who had received at least one dose of a study drug.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but these numbers cannot be extrapolated to patient populations with other clinical characteristics.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“Cardiovascular outcome events and deaths were prospectively adjudicated by two clinical-events committees (one for cardiac events and the other for neurologic events), as recommended by the Food and Drug Administration (FDA) guidelines. 9”
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of treatment was 2.6 years, and the median observation time was 3.1 years; both durations were similar in the pooled empagliflozin group and the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Members of the University of Freiburg conducted an independent statistical analysis of cardiovascular outcomes”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the the International Conference on Harmonisation Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at each participating center.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“this was a randomized, double-blind, placebo-controlled trial”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our trial provides data to support the longterm use of empagliflozin, as well as strong evidence for a reduction in cardiovascular risk.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 97.0% of patients completed the study, with 25.4% of patients prematurely discontinuing a study drug. Final vital status was available for 99.2% of patients.”
plainn = 7,028- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Safety data were reviewed by an independent academic data monitoring committee every 90 days or at the discretion of the committee.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial continued until an adjudicated primary outcome event had occurred in at least 691 patients.”
plainn = 691- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Analyses were based on a Cox proportional-hazards model, with study group, age, sex, baseline body-mass index, baseline glycated hemoglobin level, baseline eGFR, and geographic region as factors.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
The effects of empagliflozin, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk were not known before this trial.
“The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.”
The authors state this as an assumption.
In the sensitivity analysis of death from any cause, all patients lost to follow-up in the empagliflozin group were assumed to have died and all patients lost to follow-up in the placebo group were assumed to be alive.
“A sensitivity analysis of death from any cause in which it was assumed that all patients who were lost to follow-up in the empagliflozin group died and all patients who were lost to follow-up in the placebo group were alive”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“and the risk of reduction in eGFR, ESKD, or death from ESKD by 40%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“It is important to note that Black Americans were underrepresented in this trial comprising only 3.3% of all participants and that this trend towards greater amputations was not found in subsequent analyses.”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [94]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The time to benefit emerged earlier in that trial than in the present trial”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diuresis is an important mechanism for reducing blood pressure and risk for HF events (11–16,35).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduced incidence of heart failure has been observed with the use of SGLT2 inhibitors (8,194,196).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a longer duration of 8–15 years after strict glycemic control is necessary for the suppression of ASCVD risk797, 798).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [797]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In recent years, sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) have demonstrated benefits in preventing deleterious cardiorenal endpoints among individuals with type 2 diabetes, shifting disease management from a glucocentric approach to one that prioritises long-term cardiorenal health [5–7].”
From Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the risk of doubling of serum creatinine accompanied by eGFR #45 mL/min/1.73m 2 by 44%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is substantial evidence con fi rming that SGLT2i confer signi fi cant kidney and heart protective effects in these patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As discussed, there have now been 4 RCTs 87,89,90,93 and a meta-analysis of 4 of these trials 97 that have con fi rmed the signi fi cant bene fi ts of SGLT2i on clinically meaningful kidney outcomes beyond just proteinuria as a surrogate marker.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recommendation is strong due to the known kidney and/or cardiovascular protective effects in patients with T2D and CKD as shown in high-quality trials, such as EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE, DAPA-CKD, SCORED, DAPA-HF, SOLOIST, EMPEROR-Reduced and EMPEROR-Preserved.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The similar rates of amputation and fracture that we observed with canagliflozin and placebo are reassuring and consistent with trials of other SGLT2 inhibitors 6,7,20 but differ from the CANVAS Program findings.5”
From Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (281).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [281]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials have shown benefits of newer glucose-lowering medications on cardiovascular and kidney outcomes in patients with CKD with type 2 diabetes.5, 6, 7, 8, 9, 10, 11, 12, 13, 14”
From Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stratified analyses of the trials of this drug class indicate that older adults have similar or greater benefits than younger people (116-118).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stratified analyses of the trials of this drug class indicate that older adults have similar or greater benefits than younger people”
From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinical trials of other SGLT2 inhibitors have shown similar results.8,10,19”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“The pattern of cardiovascular benefits that were associated with liraglutide in our trial appears to differ from that with the sodium–glucose cotransporter 2 inhibitor empagliflozin in the previously reported EMPA-REG OUTCOME trial.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“the heterogeneity of the direction and magnitude of the effects on the components of the primary composite outcome in that trial contrasts with the consistency of the effect in the present trial.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
The cited source says what the claim attributes to it.
In the citing paper
“In EMPAREG OUTCOME, the addition of empaglifl ozin to standard care led to a signi fi cant 35% reduction in hospitalization for heart failure compared with placebo (8).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
The cited source says what the claim attributes to it.
In the citing paper
“Participants with T2D and an eGFR as low as 30 ml/min per 1.73 m 2 were included in the EMPA-REG, CANVAS, and CREDENCE trials, 87,90,93 and ef fi cacy and safety in these studies were consistent across both eGFR and albuminuria down to this threshold.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
The cited source says what the claim attributes to it.
In the citing paper
“The EMPA-REG OUTCOME trial also showed that empagliflozin was superior to placebo, 6”
From Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, trials evaluating a sodium-glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in patients with type 2 diabetes who were at high risk for cardiovascular events.2,3”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“To date, two antihyperglycemic agents have been shown to reduce the rate of cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.2,3”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“The BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) showed that treatment with empagliflozin reduced the composite outcome of MI, stroke, and cardiovascular death by 14% (absolute rate 10.5% vs. 12.1% in the placebo group, HR in the empagliflozin group 0.86 [95% CI 0.74-0.99];P = 0.04 for superiority) and cardiovascular death by 3”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
The cited source says what the claim attributes to it.
In the citing paper
“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (255).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the additional beneficial effects of GLP-1 RAs and SGLT2 inhibitors on CV outcomes in T2DM (Section 5.3), these agents should be the preferred glucose-lowering medication in overweight and obese patients with CVD and T2DM, as obesity medications have, to date, not shown to reduce CV events.[70][71][72]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SGLT2 inhibitors, compared with placebo, were associated with more new-onset AF cases in EMPA-REG OUTCOME (empagliflozin vs. placebo), but fewer incident AF cases in CANVAS (canagliflozin vs. placebo) and DECLARE-TIMI 58 (dapagliflozin vs. placebo).71,151,153,603”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Specifically, compared with placebo, empagliflozin reduced the risk of incident or worsening nephropathy (a composite of progression to UACR >300 mg/g creatinine, doubling of serum creatinine, ESKD, or death from ESKD) by 39%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“canagliflozin reduced the risk of progression of albuminuria by 27%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and semaglutide reduced the risk of new or worsening nephropathy (a composite of persistent UACR >300 mg/g creatinine, doubling of serum creatinine, or ESKD) by 36% (each P < 0.01).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“liraglutide reduced the risk of new or worsening nephropathy (a composite of persistent macroalbuminuria, doubling of serum creatinine, ESKD, or death from ESKD) by 22%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredIn the citing paper
“Among patients with type 2 diabetes at high risk for cardiovascular events, SGLT2 inhibitor use has been shown to significantly reduce death from cardiovascular causes and to lower the risk of hospitalization for heart failure and progression of kidney disease.4,6”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [4]
In the citing paper
“Empagliflozin reduced the risk of HF hospitalization by 35% in patients with and without previous HF.71”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
In the citing paper
“In the CRIC (Chronic Renal Insufficiency Cohort) study, approximately 40% of participants with established CKD had apparent treatment-resistant hypertension.22”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [22]
In the citing paper
“The pattern of use of BP lowering therapies and prevalence of resistant hypertension in CREDENCE is consistent with these data, and suggest that our findings are likely to be directly applicable to the routine care of patients with T2DM and CKD, where the burden of resistant hypertension and use of multiple BP lowering therapies is high.”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [22]
In the citing paper
“The CVOTs designed to test safety and a CKD trial (CREDENCE) were comparable in key aspects: participants with T2DM, placebo controls, SGLT2 inhibitor dose not based on glycemia, all participants treated by standard of care, and similarly defined and adjudicated outcomes.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“After a median follow-up of 3.1 years, patients treated with empagliflozin had a 14% lower relative risk for cardiovascular death, myocardial infarction, or stroke (hazard ratio [HR], 0.86; 95% CI, 0.74–0.99) (35).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“The benefit of empagliflozin on the primary CVD composite outcome was largely driven by a significant reduction in CVD death rates (3.7% vs. 5.9%; HR, 0.62 [95% CI, 0.49–0.77]).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“cardiovascular event rates remain high, even among the patients with well-managed T2DM enrolled in contemporary outcomes trials,8–10”
In the citing paper
“several cardiovascular outcomes trials (CVOTs) demonstrated that drugs that lowered HbA1c to similar levels had different effects on cardiovascular outcomes”
In the citing paper
“empagliflozin reduced MACEs by 14% (HR, 0.86 [95% CI, 0.75–0.99]) in patients with established cardiovascular disease”
In the citing paper
“which was driven primarily by a significant reduction in cardiovascular mortality (3.7% versus 5.9%; 38% RRR)”
In the citing paper
“Empagliflozin also reduced all-cause mortality (5.7% versus 8.3%; 32% RRR)”
In the citing paper
“Large cardiovascular outcome trials provided initial proof that SGLT2 inhibitors slow the progression of kidney function decline and reduce the risks of kidney outcomes in patients with T2D of whom the majority had relatively preserved kidney function (Wiviott et al., 2019; Neal et al., 2017; Zinman et al., 2015; Mosenzon et al., 2019).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Zinman et al., 2015
In the citing paper
“A limitation of our study is that it was started before GLP-1 receptor agonists 24 and SGLT2 inhibitors 25 were shown to reduce major cardiovascular events and mortality in patients with stable cardiovascular disease and type 2 diabetes.”
In the citing paper
“Rates of heart failure hospitalization have been improved in recent trials including people with type 2 diabetes, most of whom also had ASCVD, with sodium -glucose cotransporter 2 (SGLT2) inhibitors (8 -11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“and cardiovascular death by 38% (absolute rate 3.7% vs. 5.9%, HR 0.62 [95% CI 0.49 -0.77]; P < 0.001) (8).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“EMPA-REG OUTCOME showed that over a median follow-up of 3.1 years, treatment reduced the composite outcome of MI, stroke, and cardiovascular death by 14% (absolute rate 10.5% vs. 12.1% in the placebo group, HR in the empagli fl ozin group 0.86 [95% CI 0.74 -0.99]; P = 0.04 for superiority)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“In the EMPA-REG OUTCOME trial (n=7020), including patients with T2DM, established CV disease and eGFR >30 mL/min/1.73m 2 , there was a major reduction in HF hospitalization (HR 0.65) with empagliflozin compared with placebo.20”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“A significant breakthrough in contemporary cardiology was the finding that some T2DM drugs are associated with a lower risk of HF hospitalization in patients with CV disease or at high risk of CV disease (Table 8).”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Two large RCTs that assessed CV safety of the sodium-glucose co-transporter type 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have shown a significant reduction in HF hospitalization with both drugs.20,189”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Empagliflozin in EMPA-REG OUTCOME, but not canagliflozin in CANVAS, reduced all-cause and CV mortality as well as HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Darapladib (which targeted Lp-PLA 2 ) failed in SOLID-TIMI 52 128 and STABILITY 129 trials”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [128]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,765
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationAssociation of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Ronco, C., McCullough, P. A., Anker, S. D., Anand, I. S., Aspromonte, N., Bagshaw, S. M., Bellomo, R., Berl, T., Bobek, I., Cruz, D. N., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp507 · Cited by 1,137
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Research works printed but not linked: 2
- Rosenstock J, 2015, Diabetes Obes Metab
- Chilton RC, 2014, Diabetes Obes Metab
Cited by
Sorted by citations
Items 4,801–4,900 of 12,150
Htike, Z. Z., Yates, T. E., Brady, E. M., Webb, D. R., Gray, L. J., Swarbrick, D. J., McCann, G. P., Khunti, K., & Davies, M. J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0421-6 · Cited by 16
What the General Practitioner Needs to Know About Their Chronic Heart Failure Patientt
Rutten, F. H., & Gallagher, J. (2016) · Cardiac failure review · doi:10.15420/cfr.2016:18:1 · Cited by 15
The Three-Decade Long Journey in Heart Failure Drug Development
Lewis, K. S., Butler, J., Bauersachs, J. K., & Sandner, P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_101 · Cited by 16
van Meer, L., van Dongen, M., Moerland, M., de Kam, M., Cohen, A. F., & Burggraaf, J. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.292 · Cited by 15
Minato, S., Takenouchi, A., Uchida, J., Tsuboi, A., Kurata, M., Fukuo, K., & Kazumi, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2885w · Cited by 15
Mosleh, W., Sharma, A., Sidhu, M. S., Page, B. J., Sharma, U. C., & Farkouh, M. E. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6729-y · Cited by 15
Moss, A. S., Dimitropoulos, G., Connolly, D. L., & Lip, G. Y. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1350647 · Cited by 15
Adjunctive Treatments for Type 1 Diabetes
Nathan, D. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711296 · Cited by 15
Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes
Retnakaran, R. R. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.10.017 · Cited by 15
Soejima, E., Ohki, T., Kurita, Y., Yuan, X., Tanaka, K., Kakino, S., Hara, K., Nakayama, H., Tajiri, Y., & Yamada, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191147 · Cited by 15
Kaku, K., Haneda, M., Tanaka, Y., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13496 · Cited by 15
Ghosh, A., Gupta, R., Singh, P., Dutta, A., & Misra, A. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13237 · Cited by 15
Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes
Sakamoto, M., Matsutani, D., & Kayama, Y. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3584w · Cited by 15
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
Heerspink, H. J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz033 · Cited by 15
Pouwer, M. G., Heinonen, S. E., Behrendt, M., Andréasson, A., van Koppen, A., Menke, A. L., Pieterman, E. J., van den Hoek, A. M., Jukema, J. W., Leighton, B., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9727952 · Cited by 15
Kong, S. H., Koo, B. K., & Moon, M. K. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0208 · Cited by 15
Banakh, I., Kung, R., Gupta, S. K., Matthiesson, K. L., & Tiruvoipati, R. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2147 · Cited by 15
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Grenet, G., Ribault, S., Nguyen, G. B., Glais, F., Metge, A., Linet, T., Kassaï, B., Cornu, C., Bejan‐Angoulvant, T., Erpeldinger, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217701 · Cited by 15
De-Intensification of Diabetes Treatment in Elderly Patients with Type 2 Diabetes Mellitus
Pírela, D., & Garg, R. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0303 · Cited by 15
Schwartz, S. S., Grant, S. F. A., & Herman, M. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1657358 · Cited by 16
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 14
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 15
Zoungas, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13968 · Cited by 16
Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies
Molocea, C., Tsokanos, F., & Herzig, S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.006 · Cited by 15
Secondary prevention after CABG: do new agents change the paradigm?
Paquin, A., Poirier, P., Beaudoin, J., & Piché, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000783 · Cited by 15
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 15
Diabetes y enfermedad cardiovascular
Guamán, C., Acosta, W., Alvarez, C., & Hasbum, B. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.1.4 · Cited by 15
Prakoso, D., Tate, M., Blasio, M. J. D., & Ritchie, R. H. (2021) · Clinical Science · doi:10.1042/cs20210052 · Cited by 15
Sorice, G. P., Cinti, F., Leccisotti, L., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Cocchi, C., Capece, U., Ferraro, P. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01083-1 · Cited by 15
Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002496 · Cited by 16
SGLT2 inhibition and ketoacidosis – should we be concerned?
Rajeev, S. P., & Wilding, J. P. H. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.047 · Cited by 16
Age affects the prognostic impact of diabetes in chronic heart failure
Cunha, F. M., Pereira, J. C., Ribeiro, A., Amorim, M., Silva, S., Araújo, J. P., Leite-Moreira, A. F., Bettencourt, P., & Lourenço, P. (2018) · Acta Diabetologica · doi:10.1007/s00592-017-1092-9 · Cited by 15
Cardiovascular Risk and Sodium–Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
Ingelfinger, J. R., & Rosen, C. J. (2015) · New England Journal of Medicine · doi:10.1056/nejme1512602 · Cited by 15
Is the Way to Someone’s Heart Through Their Stomach?
Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 15
Khandait, H. V., Sodhi, S. S., Khandekar, N., & Bhattad, V. B. (2025) · Cardiorenal Medicine · doi:10.1159/000542633 · Cited by 17
Bond, R. M., Ivy, K. N., Crumbs, T., Purewal, V., Obang, S., & Sraow, D. I. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100983 · Cited by 15
Managing the side effects of sodium-glucose cotransporter-2 inhibitors
Kodur, N., Sharew, B., Lansang, M. C., & Tang, W. H. W. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24071 · Cited by 19
CLEMENT, M. A., & Senior, P. A. (2016) · PubMed · Cited by 14
Schernthaner, G., Lehmann, R., Prázný, M., Czupryniak, L., Ducena, K., Fasching, P., Janež, A., Karasik, A., Kempler, P., Martinka, E., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0622-7 · Cited by 14
Laufs, U., Anker, S. D., Falk, V., Pieske, B. M., Baldus, S. E., Perings, C. A., & Birner, C. M. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0143-3 · Cited by 14
Fournier’s gangrene with dapagliflozin in a rural hospital: a case report
Elbeddini, A., Tayefehchamani, Y., Davey, M., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-237784 · Cited by 14
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Hofer, F., Kazem, N., Richter, B., Sulzgruber, P., Schweitzer, R., Pailer, U., Hammer, A., Koller, L., Hengstenberg, C., & Niessner, A. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07234-7 · Cited by 14
Sagara, R., Inoue, T., Sonoda, N., Yano, C., Motoya, M., Umakoshi, H., Sakamoto, R., & Ogawa, Y. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13653 · Cited by 14
Indraratna, P., Khasanova, E., Gulsin, G. S., Τζίμας, Γ., Takagi, H., Park, K. H., Lin, F. Y.-H., Shaw, L. J., Lee, S., Narula, J., et al. (2021) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2021.11.004 · Cited by 14
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
Gessner, A., Gemeinhardt, A., Bosch, A., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01436-x · Cited by 14
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
Anker, S. D., Sander, L. E., FITCHETT, D. H., Zinman, B., Ofstad, A. P., Wanner, C., Vedin, O., Lauer, S., Verma, S., Yaggi, H. K., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109837 · Cited by 15
Self-citationIsajev, N., Bjegovic-Mikanovic, V. M., Bukumirić, Z., Vrhovac, D., & Lalic, N. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084436 · Cited by 14
Cardiovascular prevention in elderly patients.
Bonanad, C., Fernández-Olmo, R., García‐Blas, S., Alarcon, J. A., Díez‐Villanueva, P., Mansilla, C. R., García‐Pardo, H., Toledo, P., Ayesta, A., Pereira, E., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.05.004 · Cited by 15
Bidiuk, J., Gaciong, Z. A., & Sobieraj, P. (2022) · Archives of Medical Science · doi:10.5114/aoms/150029 · Cited by 14
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
He, X., Gao, X., Xie, P., Liu, Y., Bai, W., Liu, Y., & Shi, A. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s372575 · Cited by 16
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 19
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 14
SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol
Pawlos, A., Broncel, M., Woźniak, E., Markiewicz, Ł., Piastowska‐Ciesielska, A. W., & Gorzelak‐Pabiś, P. (2023) · Molecules · doi:10.3390/molecules28031112 · Cited by 14
Arnold, S. V., de Lemos, J. A., Zheng, L., Rosenson, R. S., Ballantyne, C. M., Alam, S., Bhatt, D. L., Cannon, C. P., Kosiborod, M., & the GOULD Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15032 · Cited by 14
Hammad, H., Shaaban, A., Philips, M. V., Fayed, A., & Abdelaziz, T. S. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03539-8 · Cited by 15
Speckle tracking echocardiography in early disease stages: a therapy modifier?
Mandoli, G. E., Cameli, M., Pastore, M. C., Benfari, G., Malagoli, A., D’Andrea, A., Sperlongano, S., Bandera, F., Esposito, R., Santoro, C., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001422 · Cited by 14
Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice
Zhu, Q., Zhou, Q., Luo, X.-L., Zhang, X., & Li, S.-Y. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.3.221 · Cited by 14
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 15
Deshpande, R., Patel, R., Regmi, M. R., Salih, M., Kropp, R. J., Al-bast, B., Sheikh, M. A., Sagalov, A., Kulkarni, A., Siddique, M. S., et al. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000284 · Cited by 15
Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis
Garruti, G., Baj, J., Cignarelli, A., Perrini, S., & Giorgino, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1154561 · Cited by 15
Abdelhafiz, A. H., Keegan, G. L., & Sinclair, A. J. (2023) · Metabolites · doi:10.3390/metabo13060705 · Cited by 16
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 16
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
Berra, C., Manfrini, R., Mirani, M., Bucciarelli, L., Zakaria, A., Piccini, S., Ghelardi, R., Lunati, M. E., Rodovalho, S., Bifari, F., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02115-x · Cited by 13
Li, X., Hoogenveen, R. T., Alili, M. E., Knies, S., Wang, J., Beulens, J. W. J., Elders, P. J. M., Nijpels, G., van Giessen, A., & Feenstra, T. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01286-3 · Cited by 14
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Ruhe, J., Nadal, J., Bärthlein, B., Meiselbach, H., Schultheiß, U. T., Kotsis, F., Stockmann, H., Krane, V., Sommerer, C., Loeffler, I., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad194 · Cited by 14
Self-citationTaheri, H., Chiti, H., Reshadmanesh, T., et al. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01305-2 · Cited by 14
Bhatt, A. S., Fonarow, G. C., Greene, S. J., Holmes, D. N., Alhanti, B., DeVore, A. D., Butler, J., Heidenreich, P. A., Huang, J., Kittleson, M. M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.09.005 · Cited by 16
Shiau, C.-H., Tsau, L.-Y., Kao, C., Peng, Y., Bai, C., Wu, J., & Hou, W. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03789-6 · Cited by 14
Jang, J.-H., Park, S.-Y., Kim, S., Kim, S., Oh, Y., Sa, Y. K., Hwang, Y. M., Jang, S.-W., Ihm, S., & Choi, Y. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad322 · Cited by 14
Mahmoud, M. M., Rashed, L. A., Soliman, S. A. M., Sayed, S. M., Kamel, O., Kamar, S. S., & Hussien, R. E. S. (2023) · Physiological Reports · doi:10.14814/phy2.15858 · Cited by 15
Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
Ahluwalia, T. S., Rönkkö, T., Eickhoff, M. K., Curovic, V. R., Siwy, J., Eder, S., Denicolò, S., Mayer, G. J., Mischak, H., Rossing, P. R., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.020 · Cited by 15
Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216160 · Cited by 18
Jahn, L. A., Hartline, L. M., Nguyen, T. T. D., Aylor, K. W., Horton, W. B., Liu, Z., & Barrett, E. J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2023 · Cited by 16
Kim, J. S., Lee, G., Park, K., & Oh, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0421 · Cited by 16
de Germay, S., Pambrun, É., Pariente, A., Grenet, G., Bezin, J., & Faillie, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15472 · Cited by 14
Iqbal, F., Shuja, M. H., Azam, L., Amjad, M., Manjee, K. Z., Ramzan, H., Sharif, T., Shoaib, A., Tahir, A., Kumar, S., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.001 · Cited by 17
Afshani, M. R., Torfi, E., Akiash, N., Jahanshahi, A., Mohamadi, A., & Sherafat, O. (2024) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2240130 · Cited by 14
Carberry, J., Petrie, M. C., Lee, M. M. Y., Brooksbank, K. J. M., Campbell, R. T., Good, R., Jhund, P. S., Kellman, P., Lang, N. N., Mangion, K., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14830 · Cited by 14
García‐Vega, D., Cinza‐Sanjurjo, S., Eirás, S., & González‐Juanatey, J. R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.04.032 · Cited by 15
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Mondal, S., Pramanik, S., Khare, V. R., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.240 · Cited by 15
Shafqat, A., Masters, M. C., Tripathi, U., Tchkonia, T., Kirkland, J. L., & Hashmi, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102400 · Cited by 15
Germán, J. B., Cortés, M., López, C. R., Otero, J. M. R., Chapel, J. A. E., Becerra, A. J. B., Roca, L. N., Urquía, M. T., Lázaro, A. M. P., & Tuñón, J. (2024) · Biomedicines · doi:10.3390/biomedicines12071507 · Cited by 16
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 17
Luo, Y., Ye, T., Tian, H., Song, H., Kan, C., Han, F., Hou, N., Sun, X., & Zhang, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02293-9 · Cited by 14
Role of the Pancreatic Islet Microvasculature in Health and Disease
Aplin, A. C., Aghazadeh, Y., Mohn, O. G., & Hull, R. L. (2024) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554241299862 · Cited by 21
Diabetes mellitus therapy in the light of oxidative stress and cardiovascular complications
Osman, A. A. M., Seres, A. B., & Ducza, E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108941 · Cited by 18
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Huang, B., Yen, C., Wu, C., Tsai, C., Chen, J., Hsiao, C.-C., Chen, Y., Hsieh, I.-C., & Yang, H. (2025) · Scientific Reports · doi:10.1038/s41598-024-81973-z · Cited by 14
Hyperuricemia and Cardiovascular Risk: Insights and Implications
Shubietah, A. R. M., Awashra, A., Milhem, F. S., Ghannam, M., Hattab, M. A., Rajab, I. M., Neiroukh, H., Zahdeh, M., Nouri, A., Assaassa, A., et al. (2025) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000388 · Cited by 14
Diabetische Nierenerkrankung (Update 2026)
Sourij, H., Aberer, F., Antlanger, M., Brix, J., Cejka, D., Clodi, M., Edlinger, R., Eller, K., Horn, S., Kaser, S., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0992-y · Cited by 14
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
Hu, J., Zou, P., Zhang, S., Zhou, M., & Tan, X. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258062 · Cited by 14
Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?
Bloomgarden, Z. T., EINHORN, D. F., & Handelsman, Y. (2017) · Diabetes Care · doi:10.2337/dci16-0043 · Cited by 15
Srimahachota, S., Boonyaratavej, S., Rerkpattanapipat, P., et al. (2011) · PubMed · Cited by 14
Diabetes medications and cardiovascular outcome trials: Lessons learned
Patel, K. V., Rocha, N. D. A., & McGuire, D. K. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17006 · Cited by 14
Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective
von Bonsdorff, M. B., von Bonsdorff, M. E., Haanpää, M. L., Salonen, M. K., Mikkola, T. M., Kautiainen, H., & Eriksson, J. G. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1119-x · Cited by 14
Metadata
- Authors
- Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E.
- Affiliations
- Mount Sinai Hospital (CA)
- University of Würzburg (DE)
- George Washington University (US)
- University of Toronto (CA)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Norway) (NO)
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146264128
- Semantic Scholar
- b43c548120609d766a5fec5a495baa81903ab3f2
- Cited by
- 12,315
- References
- 28
- Citations by year
- 2026: 741 · 2025: 1017 · 2024: 1082 · 2023: 1131 · 2022: 1300 · 2021: 1451 · 2020: 1380 · 2019: 1206 · 2018: 1069 · 2017: 948 · 2016: 688 · 2015: 87
- FWCI
- 567.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, heart failure hospitalization, myocardial infarction, stroke
- MeSH terms
- Aged, Benzhydryl Compounds, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
